Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
Abstract Background Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid h...
| Автори: | , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
BMC
2021-03-01
|
| Серія: | BMC Nephrology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12882-021-02304-2 |